TY - JOUR
T1 - Cost-Effectiveness Comparison of Genechip and Conventional Drug Susceptibility Test for Detecting Multidrug-Resistant Tuberculosis in China
AU - Pang, Yu
AU - Li, Qiang
AU - Ou, Xichao
AU - Sohn, Hojoon
AU - Zhang, Zhiying
AU - Li, Junchen
AU - Xia, Hui
AU - Kam, Kai Man
AU - O'Brien, Richard J.
AU - Chi, Junying
AU - Huan, Shitong
AU - Chin, Daniel P.
AU - Zhao, Yan lin
PY - 2013/7/23
Y1 - 2013/7/23
N2 - Background:Genechip (CapitalBio, Beijing, China) is a system for diagnosing resistance to rifampin and isoniazid, which shows high efficiency in detecting drug-resistant tuberculosis. Here, we firstly evaluated the costs of Genechip for detecting the drug susceptibility of Mycobacterium tuberculosis, compared to conventional drug susceptibility test (DST) in laboratories in China.Methodology/Principal Findings:Data on the costs of the two tests were collected at four hospitals. Costs were calculated using the essential factor cost calculation method. The costs of diagnosing a single case of multidrug-resistant tuberculosis (MDR-TB) using Genechip and DST were US$22.38 and $53.03, respectively. Taking into account the effect on costs from failure of a certain number of tests to accurately diagnose MDR-TB, the costs of Genechip and DST increased by 17.65% and 5.22%, respectively. The cost of both tests decreased with the increasing prevalence of MDR-TB disease, and the cost of Genechip at a sensitivity of more than 50% was lower than that of DST. When price of Genechip was varied to 50%, 80%, 150%, and 200% of the original price, the cost of Genechip at sensitivities of more than 30%, 40%, 60%, and 70%, respectively, was also lower than that of DST.Conclusions/Significance:This study showed that Genechip was a more cost-effective method of diagnosing MDR-TB compared to conventional DST.
AB - Background:Genechip (CapitalBio, Beijing, China) is a system for diagnosing resistance to rifampin and isoniazid, which shows high efficiency in detecting drug-resistant tuberculosis. Here, we firstly evaluated the costs of Genechip for detecting the drug susceptibility of Mycobacterium tuberculosis, compared to conventional drug susceptibility test (DST) in laboratories in China.Methodology/Principal Findings:Data on the costs of the two tests were collected at four hospitals. Costs were calculated using the essential factor cost calculation method. The costs of diagnosing a single case of multidrug-resistant tuberculosis (MDR-TB) using Genechip and DST were US$22.38 and $53.03, respectively. Taking into account the effect on costs from failure of a certain number of tests to accurately diagnose MDR-TB, the costs of Genechip and DST increased by 17.65% and 5.22%, respectively. The cost of both tests decreased with the increasing prevalence of MDR-TB disease, and the cost of Genechip at a sensitivity of more than 50% was lower than that of DST. When price of Genechip was varied to 50%, 80%, 150%, and 200% of the original price, the cost of Genechip at sensitivities of more than 30%, 40%, 60%, and 70%, respectively, was also lower than that of DST.Conclusions/Significance:This study showed that Genechip was a more cost-effective method of diagnosing MDR-TB compared to conventional DST.
UR - http://www.scopus.com/inward/record.url?scp=84880757326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880757326&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0069267
DO - 10.1371/journal.pone.0069267
M3 - Article
C2 - 23935970
AN - SCOPUS:84880757326
SN - 1932-6203
VL - 8
JO - PloS one
JF - PloS one
IS - 7
M1 - e69267
ER -